Item 7.01.Regulation FD Disclosure.
On April 17, 2023, Elevation Oncology, Inc. (the “Company”) issued a press release announcing preclinical proof-of-concept data and a clinical case study for its lead candidate, EO-3021. The Company also hosted an oral presentation as part of the New Drugs on the Horizon special session at the American Association for Cancer Research Annual Meeting 2023 regarding the preclinical proof-of-concept data and clinical case study.
A copy of the press release and corporate presentation presented during the oral presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
The information furnished in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 8.01.Other Events.
On April 17, 2023, the Company presented preclinical proof-of-concept data and a clinical case study for its lead candidate, EO-3021.
The clinical case study is from an ongoing Phase 1 clinical trial being conducted in China by the Company’s partner, CSPC Pharmaceutical Group Limited. The clinical case study involves a patient with metastatic gastric cancer who achieved a confirmed partial response on treatment with EO-3021.
Key findings from the preclinical study include:
| ● | EO-3021 is an antibody-drug conjugate (ADC) comprised of a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. |
| ● | EO-3021 retains antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). |
| ● | EO-3021 reduction in cell viability requires Claudin 18.2 expression in vitro with no effects seen on Claudin 18.2-negative cells. |
| ● | EO-3021 demonstrated anti-tumor activity in in vivo xenograft models of pancreatic and gastric cancers expressing varying levels of Claudin 18.2. |
| o | A single dose of EO-3021 demonstrated tumor regression across low, medium, and high Claudin 18.2-expressing models, with a lower minimal efficacious dose in models with medium and high levels of Claudin 18.2 relative to models with low levels of Claudin 18.2. |
| o | EO-3021 outperformed standard of care chemotherapy in gastric and pancreatic cancer in vivo models. |
Key findings from the clinical case study include:
| ● | Patient was treated with dose level 2, or 1.0 mg/kg EO-3021, intravenously, every three weeks for 12 cycles (treatment ongoing). |
| ● | The best overall response, as evaluated per RECIST v1.1, was a confirmed partial response (66.7% maximal tumor reduction). |
| ● | Duration of response was approximately 11 months and ongoing. |
